How many people are employed at Servier Symphogen A/S?

163 people are employed at Servier Symphogen A/S.

Where is Servier Symphogen A/S based?

Servier Symphogen A/S is based in Ballerup, Denmark.

When was Servier Symphogen A/S founded?

Servier Symphogen A/S was founded in 2000.

What is Servier Symphogen A/S's website?

You can visit Servier Symphogen A/S's website at https://symphogen.com.

Servier Symphogen A/S

10013267Active

Advancing innovative antibody therapeutics to improve cancer patient outcomes globally.

Corporate subsidiary and research centersymphogen.com

163
Employees: Unknown
Revenue: 2000
Founded

Servier Symphogen is the dedicated Antibody Center of Excellence within the global Servier Group, specializing in the discovery and early development of innovative antibody therapeutics. Founded in 2000 and acquired by Servier in 2020, the company focuses primarily on advancing treatments for oncolo...

Keywords

Antibody EngineeringAntibody PlatformAntibody TherapeuticsBallerupBiologicsBiotechnologyCancer TreatmentClinical DevelopmentDrug DesignDrug DiscoveryHealthcare InnovationImmunologyImmuno-oncologyLife SciencesMonoclonal AntibodiesOncologyPharmaceutical ResearchR&DServier GroupTherapeutic Development

Tech Stack

Tailwind CSSVimeoBootstrapWordPressGoogle Analytics

Decision Makers

No decision makers found yet

Similar Companies

20 similar companies in Funnelfeedr

Y-mAbs Therapeutics A/S

43 employees

Developing innovative radioimmunotherapy and antibody-based treatments for challenging cancers.

SERVIER DANMARK A/S

5 employees

A global pharmaceutical company focused on cardiovascular and oncology research.

GENMAB A/S

562 employees

Pioneering biotechnology company developing innovative antibody therapeutics for serious diseases.

BioInvent International Aktiebolag

100–199 employees

Clinical-stage company developing novel immuno-oncology antibody therapeutics for cancer.

Chiesi Pharma Danmark, filial af Chiesi Pharma AB

13 employees

International pharmaceutical group focused on innovative respiratory and rare diseases.